YOLFTbeta
Isofol Medical AB

Isofol Medical AB

ISOFOL · ST · Healthcare / Biotechnology

1.02SEK-0.15 (-12.54%)

Price History

Full chart

Market Stats

Previous Close1.16
Open1.14
Day Range0.987 – 1.14
52-Week Range0.5515 – 0.99
Volume3.79M
Market Cap239.09M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.17
Dividend Yield0.00%
Beta1.02
50-Day Avg0.792
200-Day Avg0.7213

About

Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in 2008 and is based in Gothenburg, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Petter Segelman Lindqvist M.Sc.
  • Employees7
  • HeadquartersBiotech Center, Gothenburg, Sweden, 413 46, Sweden
  • Websitehttps://isofolmedical.com

Leadership

  • Mr. Petter Segelman Lindqvist M.Sc.Chief Executive Officer · b. 1981
  • Ms. Margareta Hagman M.Sc.Chief Financial Officer · b. 1966
  • Dr. Roger Tell M.D., Ph.D.Chief Medical Officer · b. 1965
  • Mr. John ProffettBusiness Development & Chief Business Officer

Financials

Income Statement

Currency: SEK2011-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-187.00K508.00K227.00K0037.12M22.41M12.80M721.00K00
Growth (%)--+171.66%-55.31%-100.00%---39.63%-42.89%-94.37%-100.00%-
Cost of Revenue-110.39K132.00K157.00K157.00K1.55M199.53M226.03M178.50M35.14M38.73M-
Gross Profit-76.61K376.00K70.00K-157.00K-1.55M-162.42M-174.31M-165.71M-34.41M-38.73M-
Gross Margin-40.97%74.02%30.84%---437.55%-777.90%-1294.89%-4773.23%--
Operating Expense-40.76M64.39M72.66M89.69M166.25M24.08M30.16M1.75M7.27M8.47M-
Operating Income-10.53M-40.69M-64.02M-72.59M-89.85M-167.80M-186.49M-204.47M-167.46M-41.68M-47.21M-54.76M
Operating Margin--21758.29%-12601.77%-31976.65%---502.42%-912.51%-1308.59%-5781.28%--
EBITDA-10.42M-40.58M-64.82M-71.88M-89.69M-159.85M-187.07M-198.49M-159.73M-37.02M-47.21M-54.76M
EBITDA Margin--21699.47%-12759.65%-31664.32%---503.97%-885.83%-1248.15%-5135.09%--
Net Income-10.60M-40.69M-64.02M-72.03M-83.13M-161.58M-188.99M-200.25M-159.79M-37.07M-43.49M-54.17M
Net Income Margin--21758.82%-12601.97%-31733.48%---509.15%-893.70%-1248.68%-5141.61%--
R&D-----------39.90M
Interest Expense-1.00K2.00K6.00K638.00K183.00K153.00K168.00K44.00K10.00K01.00K
Interest Expense % of Total Revenue-0.53%0.39%2.64%--0.41%0.75%0.34%1.39%--

Balance Sheet

Currency: SEK2011-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets10.37M9.78M22.89M361.28M288.55M146.47M148.13M401.36M213.46M140.60M98.42M129.40M
Total Liabilities2.49M8.46M16.79M18.24M23.54M41.56M81.56M83.13M54.99M19.16M20.47M21.52M
Total Equity7.89M1.32M6.10M343.03M265.01M104.91M66.57M318.23M158.48M121.43M77.94M107.87M
Cash8.40M7.29M19.11M357.33M272.90M126.98M116.39M379.45M190.58M138.15M96.16M41.99M
Total Debt-----4.19M3.12M1.65M3.95M---
Net Debt-8.40M-7.29M-19.11M-357.33M-272.90M-124.22M-113.28M-377.80M-186.63M-138.15M-96.16M-41.99M

Cash Flow

Currency: SEK2011-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--36.77M-56.90M-61.94M-92.46M-147.21M-160.27M-188.43M-190.97M-52.54M-41.99M-51.94M
Investing Cash Flow--137.00K-73.00K-75.00K-324.00K-324.00K1.00K-0101.00K00
Financing Cash Flow-37.88M68.80M400.24M5.10M-243.00K150.01M450.48M23.00K-50.00K084.07M
Capital Expenditure0137.00K73.00K75.00K324.00K324.00K0000051.94M
Free Cash Flow--36.90M-56.98M-62.02M-92.46M-147.53M-160.27M-188.43M-190.97M-52.54M-41.99M-51.94M
FCF to OCF-100.37%100.13%100.12%100.00%100.22%100.00%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateMay 16, 2017Aug 21, 2017Nov 20, 2017Feb 20, 2018May 16, 2018Aug 21, 2018Nov 23, 2018Feb 26, 2019May 23, 2019Aug 22, 2019Nov 13, 2019Feb 19, 2020May 14, 2020Aug 21, 2020Nov 13, 2020Feb 26, 2021May 14, 2021Aug 24, 2021Nov 11, 2021Feb 24, 2022May 12, 2022Aug 23, 2022Nov 11, 2022Feb 22, 2023May 3, 2023Aug 22, 2023Nov 10, 2023Feb 20, 2024May 8, 2024Aug 21, 2024Nov 12, 2024Feb 19, 2025May 21, 2025Jul 18, 2025Nov 12, 2025Feb 19, 2026May 19, 2026Aug 26, 2026
EPS Estimate-0.57-1.06-0.65-0.67----1.21-0.81-0.91-1.02-1.48-1.61-1.691.73-0.66-0.68-0.26-0.28-0.32-0.31-0.32-0.32-0.48-0.19-0.15------------
EPS Actual-0.79-0.43-0.73-0.93-0.35-0.30-0.31-0.91-0.84-1.08-1.31-1.81-1.74-1.04-0.36-0.66-0.51-0.48-0.32-0.38-0.30-0.33-0.20-0.16-0.09-0.05-0.04-0.06-0.05-0.07-0.07-0.08-0.08-0.09-0.05-0.05-0.05-0.05
Surprise-38.60%59.43%-12.31%-38.81%---24.79%-3.70%-18.68%-28.43%-22.30%-8.07%38.46%-120.81%0.00%25.00%-84.62%-14.29%-18.75%3.23%-3.13%37.50%66.67%52.63%66.67%------------
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-market-Pre-market-

Key Statistics & Ratios

Market Cap239.09M
Enterprise Value144.77M
Trailing P/E0.00
Forward P/E0.00
Price / Sales5.91
Price / Book2.73
EPS-0.17
Book Value0.296
Revenue (TTM)0
Gross Profit (TTM)-40.16M
EBITDA-54.76M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-78.31%
Return on Assets-39.03%
Shares Outstanding320.49M
Shares Float228.15M
Beta1.02
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%